Myriam Chalabi, Medical Oncologist and Cancer Immunotherapy researcher, Gastrointestinal Oncology at Antoni van Leeuwenhoek, shared on X:
“Great overview by Michael Overman of pMMR CRC and efforts to modulate for immunotherapy response. Important to learn from negative studies, but also consider that responses might be different in earlier disease stages.”
More posts featuring ESMOGI25.